Glycosylation of Therapeutic Proteins

[1]  Gillian M. Keating,et al.  Lutropin Alfa , 2012, Drugs.

[2]  G. Keating,et al.  Spotlight on Agalsidase Beta in Fabry Disease1 , 2012, BioDrugs.

[3]  P. Kallio,et al.  The production of biopharmaceuticals in plant systems. , 2009, Biotechnology advances.

[4]  R. Horstkorte,et al.  Increasing the sialylation of therapeutic glycoproteins: the potential of the sialic acid biosynthetic pathway. , 2009, Journal of pharmaceutical sciences.

[5]  Z. Li,et al.  Optimal and consistent protein glycosylation in mammalian cell culture. , 2009, Glycobiology.

[6]  H. Maynard,et al.  Synthesis of a pyridyl disulfide end-functionalized glycopolymer for conjugation to biomolecules and patterning on gold surfaces. , 2009, Biomacromolecules.

[7]  T. Braulke,et al.  Glycosylation- and phosphorylation-dependent intracellular transport of lysosomal hydrolases , 2009, Biological chemistry.

[8]  R. Jefferis,et al.  Recombinant antibody therapeutics: the impact of glycosylation on mechanisms of action. , 2009, Trends in pharmacological sciences.

[9]  B. G. Davis,et al.  Glycoprotein synthesis: an update. , 2009, Chemical Reviews.

[10]  B. Wren,et al.  N-linked glycosylation in bacteria: an unexpected application. , 2009, Future microbiology.

[11]  P. Devroey,et al.  Advances in recombinant DNA technology: corifollitropin alfa, a hybrid molecule with sustained follicle-stimulating activity and reduced injection frequency. , 2009, Human reproduction update.

[12]  Y. Chiba,et al.  Glycan engineering and production of 'humanized' glycoprotein in yeast cells. , 2009, Biological & pharmaceutical bulletin.

[13]  D. Stuart,et al.  Carbohydrate and domain architecture of an immature antibody glycoform exhibiting enhanced effector functions. , 2009, Journal of molecular biology.

[14]  S. Nishimura,et al.  Chemoenzymatic synthesis of glycosylated glucagon-like peptide 1: effect of glycosylation on proteolytic resistance and in vivo blood glucose-lowering activity. , 2009, Journal of the American Chemical Society.

[15]  Kai Griebenow,et al.  Effects of glycosylation on the stability of protein pharmaceuticals. , 2009, Journal of pharmaceutical sciences.

[16]  M. Otagiri,et al.  Altered chain-length and glycosylation modify the pharmacokinetics of human serum albumin. , 2009, Biochimica et biophysica acta.

[17]  P. Drakakis,et al.  Corifollitropin alfa, a long-acting follicle-stimulating hormone agonist for the treatment of infertility. , 2009, Current opinion in investigational drugs.

[18]  S. Withers,et al.  Emerging methods for the production of homogeneous human glycoproteins. , 2009, Nature chemical biology.

[19]  Roy Jefferis,et al.  Glycosylation as a strategy to improve antibody-based therapeutics , 2009, Nature Reviews Drug Discovery.

[20]  Teresa Mitchell,et al.  Production of monoclonal antibodies by glycoengineered Pichia pastoris. , 2009, Journal of biotechnology.

[21]  J. Roy.  Glycosylation of antibody therapeutics: optimisation for purpose. , 2009 .

[22]  J. Lustbader,et al.  Efficacy of native and hyperglycosylated follicle-stimulating hormone analogs for promoting fertility in female mice. , 2009, Fertility and sterility.

[23]  R. Jefferis.  Glycosylation of antibody therapeutics: optimisation for purpose. , 2009, Methods in molecular biology.

[24]  M. Beck.  Agalsidase alfa for the treatment of Fabry disease: new data on clinical efficacy and safety. , 2009, Expert opinion on biological therapy.

[25]  T. Wurch,et al.  Trends in glycosylation, glycoanalysis and glycoengineering of therapeutic antibodies and Fc-fusion proteins. , 2008, Current pharmaceutical biotechnology.

[26]  C Simone Fishburn,et al.  The pharmacology of PEGylation: balancing PD with PK to generate novel therapeutics. , 2008, Journal of pharmaceutical sciences.

[27]  T. Raju,et al.  Terminal sugars of Fc glycans influence antibody effector functions of IgGs. , 2008, Current opinion in immunology.

[28]  M. O'Callaghan,et al.  Biochemical and pharmacological characterization of different recombinant acid alpha-glucosidase preparations evaluated for the treatment of Pompe disease. , 2008, Molecular genetics and metabolism.

[29]  P. Højrup,et al.  The Function of the Human Interferon-β1a Glycan Determined in Vivo , 2008, Journal of Pharmacology and Experimental Therapeutics.

[30]  Kisung Ko,et al.  Glyco-engineering of biotherapeutic proteins in plants. , 2008, Molecules and cells.

[31]  J. Carpenter,et al.  Effects of solution conditions, processing parameters, and container materials on aggregation of a monoclonal antibody during freeze-thawing. , 2008, Journal of pharmaceutical sciences.

[32]  Yeon‐Gu Kim,et al.  Assessment of cell engineering strategies for improved therapeutic protein production in CHO cells , 2008, Biotechnology journal.

[33]  J. V. van Mourik,et al.  Survival of von Willebrand factor released following DDAVP in a type 1 von Willebrand disease cohort: Influence of glycosylation, proteolysis and gene mutations , 2008, Thrombosis and Haemostasis.

[34]  R. Kontermann,et al.  N-Glycosylation as Novel Strategy to Improve Pharmacokinetic Properties of Bispecific Single-chain Diabodies* , 2008, Journal of Biological Chemistry.

[35]  M. Etcheverrigaray,et al.  Novel long-lasting interferon alpha derivatives designed by glycoengineering. , 2008, Biochimie.

[36]  Henrik Clausen,et al.  Mucin-type O-glycosylation and its potential use in drug and vaccine development. , 2008, Biochimica et biophysica acta.

[37]  H. Longhurst.  Rhucin, a recombinant C1 inhibitor for the treatment of hereditary angioedema and cerebral ischemia. , 2008, Current opinion in investigational drugs.

[38]  H. Kim,et al.  The glycosylation and in vivo stability of human granulocyte-macrophage colony-stimulating factor produced in rice cells. , 2008, Biological & pharmaceutical bulletin.

[39]  O. Christophe,et al.  Clearance of von Willebrand factor , 2008, Thrombosis and Haemostasis.

[40]  Fred Jacobson,et al.  Protein aggregation and bioprocessing , 2006, The AAPS Journal.

[41]  Kurt Forrer,et al.  Effect of constant and variable domain glycosylation on pharmacokinetics of therapeutic antibodies in mice. , 2008, Biologicals : journal of the International Association of Biological Standardization.

[42]  D. Lillicrap.  Extending half-life in coagulation factors: where do we stand? , 2008, Thrombosis research.

[43]  S. Evans,et al.  Site-directed conjugation of "clicked" glycopolymers to form glycoprotein mimics: binding to mammalian lectin and induction of immunological function. , 2007, Journal of the American Chemical Society.

[44]  Christopher J Roberts,et al.  Non‐native protein aggregation kinetics , 2007, Biotechnology and bioengineering.

[45]  Y. Jigami,et al.  Production of humanized glycoproteins in bacteria and yeasts. , 2007, Current opinion in chemical biology.

[46]  B. G. Davis,et al.  Site-selective glycosylation of proteins: creating synthetic glycoproteins , 2007, Nature Protocols.

[47]  T. Gerngross,et al.  Glycosylation engineering in yeast: the advent of fully humanized yeast. , 2007, Current opinion in biotechnology.

[48]  M. Bawendi,et al.  Renal clearance of quantum dots , 2007, Nature Biotechnology.

[49]  D. Jarvis,et al.  Protein N-glycosylation in the baculovirus-insect cell system. , 2007, Current drug targets.

[50]  Eric D. Dodds,et al.  Site determination of protein glycosylation based on digestion with immobilized nonspecific proteases and Fourier transform ion cyclotron resonance mass spectrometry. , 2007, Journal of proteome research.

[51]  Wei-Shou Hu,et al.  Systems Analysis of N-Glycan Processing in Mammalian Cells , 2007, PloS one.

[52]  William B. Smith,et al.  Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease. , 2007, Clinical therapeutics.

[53]  R. J. Solá,et al.  Modulation of protein biophysical properties by chemical glycosylation: biochemical insights and biomedical implications , 2007, Cellular and Molecular Life Sciences.

[54]  Johannes Kneer,et al.  Selective clearance of glycoforms of a complex glycoprotein pharmaceutical caused by terminal N-acetylglucosamine is similar in humans and cynomolgus monkeys. , 2007, Glycobiology.

[55]  Richard O'Kennedy,et al.  Sialic acids: carbohydrate moieties that influence the biological and physical properties of biopharmaceutical proteins and living cells. , 2007, Drug discovery today.

[56]  R. Werner,et al.  Glycosylation of therapeutic proteins in different production systems , 2007, Acta paediatrica.

[57]  W. Tanner,et al.  Protein Glycosylation, Conserved from Yeast to Man: A Model Organism Helps Elucidate Congenital Human Diseases , 2007 .

[58]  A. Hawe,et al.  Formulation Development for Hydrophobic Therapeutic Proteins , 2007, Pharmaceutical development and technology.

[59]  B. Scallon,et al.  Fc Glycans Terminated with N‐Acetylglucosamine Residues Increase Antibody Resistance to Papain , 2007, Biotechnology progress.

[60]  G. Keating,et al.  Spotlight on agalsidase beta in Fabry disease. , 2007, BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy.

[61]  Wei Wang,et al.  Antibody structure, instability, and formulation. , 2007, Journal of pharmaceutical sciences.

[62]  E. Alba Conejo,et al.  Erythropoietin pharmacology , 2007, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

[63]  G. Keating,et al.  Agalsidase Beta: a review of its use in the management of Fabry disease. , 2007, Drugs.

[64]  Chi‐Huey Wong,et al.  Strategies for the preparation of homogenous glycoproteins. , 2006, Current opinion in chemical biology.

[65]  Jack Hoopes,et al.  Humanization of Yeast to Produce Complex Terminally Sialylated Glycoproteins , 2006, Science.

[66]  R. J. Solá,et al.  Engineering of protein thermodynamic, kinetic, and colloidal stability: Chemical Glycosylation with monofunctionally activated glycans , 2006, Biotechnology and bioengineering.

[67]  Hongcheng Liu,et al.  Effect of posttranslational modifications on the thermal stability of a recombinant monoclonal antibody. , 2006, Immunology letters.

[68]  Terrance A Stadheim,et al.  Challenges in therapeutic glycoprotein production. , 2006, Current opinion in biotechnology.

[69]  H. Maynard,et al.  Biotinylated glycopolymers synthesized by atom transfer radical polymerization. , 2006, Biomacromolecules.

[70]  Bo Yang,et al.  Effect of glycosylation at Asn302 of pro-urokinase on its stability in culture supernatant. , 2006, Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih.

[71]  Barbara Imperiali,et al.  Asparagine-linked protein glycosylation: from eukaryotic to prokaryotic systems. , 2006, Glycobiology.

[72]  B. Scallon,et al.  Glycosylation in the Fc domain of IgG increases resistance to proteolytic cleavage by papain. , 2006, Biochemical and biophysical research communications.

[73]  J. M. Beals,et al.  Enhancing exposure of protein therapeutics. , 2006, Drug discovery today. Technologies.

[74]  Youwei Jiang,et al.  Optimization of humanized IgGs in glycoengineered Pichia pastoris , 2006, Nature Biotechnology.

[75]  Harvey F Lodish,et al.  Cellular Trafficking and Degradation of Erythropoietin and Novel Erythropoiesis Stimulating Protein (NESP)* , 2006, Journal of Biological Chemistry.

[76]  R. Jefferis.  Glycosylation of Recombinant Antibody Therapeutics , 2008, Biotechnology progress.

[77]  Charles S Henry,et al.  Colloidal behavior of proteins: effects of the second virial coefficient on solubility, crystallization and aggregation of proteins in aqueous solution. , 2005, Current pharmaceutical biotechnology.

[78]  Sylvie Garneau-Tsodikova,et al.  Protein posttranslational modifications: the chemistry of proteome diversifications. , 2005, Angewandte Chemie.

[79]  A. Eerenberg,et al.  A phase I study of recombinant human C1 inhibitor in asymptomatic patients with hereditary angioedema. , 2005, The Journal of allergy and clinical immunology.

[80]  S. Elliott,et al.  Glycoengineering: the effect of glycosylation on the properties of therapeutic proteins. , 2005, Journal of pharmaceutical sciences.

[81]  J. Lustbader,et al.  Effects of long-acting recombinant human follicle-stimulating hormone analogs containing N-linked glycosylation on murine folliculogenesis. , 2005, Fertility and sterility.

[82]  Daniel E. Otzen,et al.  Protein drug stability: a formulation challenge , 2005, Nature Reviews Drug Discovery.

[83]  Wei Wang,et al.  Protein aggregation and its inhibition in biopharmaceutics. , 2005, International journal of pharmaceutics.

[84]  L. Brown.  Commercial challenges of protein drug delivery , 2005, Expert opinion on drug delivery.

[85]  I. Mahmood,et al.  Pharmacokinetic and Pharmacodynamic Considerations in the Development of Therapeutic Proteins , 2005, Clinical pharmacokinetics.

[86]  K. Medzihradszky.  Characterization of protein N-glycosylation. , 2005, Methods in enzymology.

[87]  J. Peter-Katalinic,et al.  Methods in enzymology: O-glycosylation of proteins. , 2005, Methods in enzymology.

[88]  S. Elliott,et al.  Control of rHuEPO biological activity: the role of carbohydrate. , 2004, Experimental hematology.

[89]  P. Devroey,et al.  Pharmacodynamics of a single low dose of long-acting recombinant follicle-stimulating hormone (FSH-carboxy terminal peptide, corifollitropin alfa) in women with World Health Organization group II anovulatory infertility. , 2004, The Journal of clinical endocrinology and metabolism.

[90]  T. Gerngross,et al.  Advances in the production of human therapeutic proteins in yeasts and filamentous fungi , 2004, Nature Biotechnology.

[91]  L. Hsieh‐Wilson.  Tailor-made glycoproteins. , 2004, Trends in biotechnology.

[92]  R. Ogden,et al.  Long-acting follicle-stimulating hormone analogs containing N-linked glycosylation exhibited increased bioactivity compared with o-linked analogs in female rats. , 2004, The Journal of clinical endocrinology and metabolism.

[93]  M. Burnier,et al.  Efficacy of enzyme replacement therapy in Fabry disease. , 2004, Current medicinal chemistry. Cardiovascular and hematological agents.

[94]  B. Meibohm,et al.  Pharmacokinetic aspects of biotechnology products. , 2004, Journal of pharmaceutical sciences.

[95]  G. Walsh.  Second-generation biopharmaceuticals. , 2004, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[96]  P. Devroey,et al.  Induction of multiple follicular development by a single dose of long-acting recombinant follicle-Stimulating hormone (FSH-CTP, corifollitropin alfa) for controlled ovarian stimulation before in vitro fertilization. , 2004, The Journal of clinical endocrinology and metabolism.

[97]  T. Gerngross,et al.  Production of therapeutic proteins in fungal hosts , 2004, Expert opinion on biological therapy.

[98]  R. Raines,et al.  Glycosylation of onconase increases its conformational stability and toxicity for cancer cells. , 2004, Biochemical and biophysical research communications.

[99]  C. Carter,et al.  Human serum inactivates non-glycosylated but not glycosylated granulocyte colony stimulating factor by a protease dependent mechanism: significance of carbohydrates on the glycosylated molecule. , 2004, Biologicals : journal of the International Association of Biological Standardization.

[100]  E. Muslin,et al.  Effect of adding and removing N-glycosylation recognition sites on the thermostability of barley alpha-glucosidase. , 2004, Protein engineering, design & selection : PEDS.

[101]  H. Hayashi,et al.  Glycosylated human interleukin-1α, neoglyco IL-1α, coupled with N-acetylneuraminic acid exhibits selective activities in vivo and altered tissue distribution , 2000, Glycoconjugate Journal.

[102]  S. Pohl,et al.  Genetic engineering of recombinant glycoproteins and glycosylation pathway in mammalian host cells , 1999, Glycoconjugate Journal.

[103]  Adrian Whitty,et al.  Structural and Functional Differences Between Glycosylated and Non-glycosylated Forms of Human Interferon-β (IFN-β) , 1998, Pharmaceutical Research.

[104]  R. Borchardt,et al.  Stability of Protein Pharmaceuticals , 1989, Pharmaceutical Research.

[105]  R. Hopkin,et al.  Enzyme therapy for lysosomal storage disease: principles, practice, and prospects. , 2003, Annual review of genomics and human genetics.

[106]  M. Koury.  Sugar coating extends half-lives and improves effectiveness of cytokine hormones. , 2003, Trends in biotechnology.

[107]  Y. Combarnous,et al.  Fast renal trapping of porcine Luteinizing Hormone (pLH) shown by 123I-scintigraphic imaging in rats explains its short circulatory half-life , 2003, Reproductive biology and endocrinology : RB&E.

[108]  P. Caliceti,et al.  Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates. , 2003, Advanced drug delivery reviews.

[109]  S. A. Marshall,et al.  Designing proteins for therapeutic applications. , 2003, Current opinion in structural biology.

[110]  B. van den Hazel,et al.  Glycosylation of an N-terminal extension prolongs the half-life and increases the in vivo activity of follicle stimulating hormone. , 2003, The Journal of clinical endocrinology and metabolism.

[111]  G. Gregoriadis,et al.  Polysialylated insulin: synthesis, characterization and biological activity in vivo. , 2003, Biochimica et biophysica acta.

[112]  Theodore W Randolph,et al.  Roles of conformational stability and colloidal stability in the aggregation of recombinant human granulocyte colony‐stimulating factor , 2003, Protein science : a publication of the Protein Society.

[113]  Byung-Kwon Choi,et al.  Use of combinatorial genetic libraries to humanize N-linked glycosylation in the yeast Pichia pastoris , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[114]  L. Buck,et al.  Enhancement of therapeutic protein in vivo activities through glycoengineering , 2003, Nature Biotechnology.

[115]  J. Egrie,et al.  Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. , 2003, Experimental hematology.

[116]  Huawei Qiu,et al.  A biochemical and pharmacological comparison of enzyme replacement therapies for the glycolipid storage disorder Fabry disease. , 2003, Glycobiology.

[117]  S. A. Marshall,et al.  Rational design and engineering of therapeutic proteins. , 2003, Drug discovery today.

[118]  M. Mann,et al.  Proteomic analysis of post-translational modifications , 2003, Nature Biotechnology.

[119]  Teresa Mitchell,et al.  Production of complex human glycoproteins in yeast. , 2003, Science.

[120]  Mark C Manning,et al.  The stability factor: importance in formulation development. , 2002, Current pharmaceutical biotechnology.

[121]  C. Begley,et al.  Recombinant human thrombopoietin: basic biology and evaluation of clinical studies. , 2002, Blood.

[122]  W. Jelkmann.  The enigma of the metabolic fate of circulating erythropoietin (Epo) in view of the pharmacokinetics of the recombinant drugs rhEpo and NESP , 2002, European journal of haematology.

[123]  P. Weigel,et al.  Glycans as endocytosis signals: the cases of the asialoglycoprotein and hyaluronan/chondroitin sulfate receptors. , 2002, Biochimica et biophysica acta.

[124]  C. Klipping,et al.  Single dose pharmacokinetics and effects on follicular growth and serum hormones of a long-acting recombinant FSH preparation (FSH-CTP) in healthy pituitary-suppressed females. , 2002, Human reproduction.

[125]  I. Macdougall.  Optimizing the use of erythropoietic agents-- pharmacokinetic and pharmacodynamic considerations. , 2002, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[126]  D. Andersen,et al.  Recombinant protein expression for therapeutic applications. , 2002, Current opinion in biotechnology.

[127]  R. Sylvester.  Clinical applications of colony-stimulating factors: a historical perspective. , 2002, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[128]  Theodore W Randolph,et al.  Long‐Term Storage of Proteins , 2002, Current protocols in protein science.

[129]  C. Andersen,et al.  Assessment of the in vitro and in vivo biological activities of the human follicle-stimulating isohormones , 2002, Molecular and Cellular Endocrinology.

[130]  Erwin Freund,et al.  Protein formulation and fill-finish operations. , 2002, Biotechnology annual review.

[131]  C. Bertozzi,et al.  Homogeneous glycopeptides and glycoproteins for biological investigation. , 2002, Annual review of biochemistry.

[132]  J. E. Wraith.  Lysosomal disorders. , 2002, Seminars in neonatology : SN.

[133]  R. Egleton,et al.  Improved blood-brain barrier penetration and enhanced analgesia of an opioid peptide by glycosylation. , 2001, The Journal of pharmacology and experimental therapeutics.

[134]  J. Briggs,et al.  Glycoengineering of therapeutic glycoproteins: in vitro galactosylation and sialylation of glycoproteins with terminal N-acetylglucosamine and galactose residues. , 2001, Biochemistry.

[135]  G. Gregoriadis,et al.  The effect of polysialylation on the immunogenicity and antigenicity of asparaginase: implication in its pharmacokinetics. , 2001, International journal of pharmaceutics.

[136]  E. Pellizzari,et al.  Human FSH isoforms: carbohydrate complexity as determinant of in-vitro bioactivity , 2001, Molecular and Cellular Endocrinology.

[137]  M Schwaiger,et al.  Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[138]  J. Belmont,et al.  Enzyme-replacement therapy in mucopolysaccharidosis I. , 2001, The New England journal of medicine.

[139]  S J Prestrelski,et al.  Factors affecting short-term and long-term stabilities of proteins. , 2001, Advanced drug delivery reviews.

[140]  G. Gregoriadis,et al.  Polysialic acids: potential in improving the stability and pharmacokinetics of proteins and other therapeutics , 2000, Cellular and Molecular Life Sciences CMLS.

[141]  J. Zhang,et al.  Glycosylation of prourokinase produced by Pichia pastoris impairs enzymatic activity but not secretion. , 2000, Protein expression and purification.

[142]  V. Hruby,et al.  Improved bioavailability to the brain of glycosylated Met-enkephalin analogs , 2000, Brain Research.

[143]  V. Bhakta,et al.  Modulation of clearance of recombinant serum albumin by either glycosylation or truncation. , 2000, Thrombosis research.

[144]  V. Ananthanarayanan,et al.  Mutation of any site of N-linked glycosylation accelerates the in vivo clearance of recombinant rabbit antithrombin. , 2000, Thrombosis research.

[145]  W. Wang,et al.  Lyophilization and development of solid protein pharmaceuticals. , 2000, International journal of pharmaceutics.

[146]  D. Casley,et al.  O-glycosylation delays the clearance of human IGF-binding protein-6 from the circulation. , 2000, European journal of endocrinology.

[147]  D. Brooks,et al.  Enzyme Replacement Therapy in Mucopolysaccharidosis I: Altered Distribution and Targeting of α-l-Iduronidase in Immunized Rats , 2000 .

[148]  J. Lee.  Biopharmaceutical formulation. , 2000, Current opinion in biotechnology.

[149]  R Apweiler,et al.  On the frequency of protein glycosylation, as deduced from analysis of the SWISS-PROT database. , 1999, Biochimica et biophysica acta.

[150]  G. Hammond,et al.  Influence of glycosylation on the clearance of recombinant human sex hormone-binding globulin from rabbit blood , 1999, The Journal of Steroid Biochemistry and Molecular Biology.

[151]  W Wang,et al.  Instability, stabilization, and formulation of liquid protein pharmaceuticals. , 1999, International journal of pharmaceutics.

[152]  S. Canaan,et al.  Site-directed removal of N-glycosylation sites in human gastric lipase. , 1999, European journal of biochemistry.

[153]  R. Ghirlando,et al.  Glycosylation of human IgG-Fc: influences on structure revealed by differential scanning micro-calorimetry. , 1999, Immunology letters.

[154]  G. Gregoriadis,et al.  Polysialic acids: potential role in therapeutic constructs. , 1999, Biotechnology & genetic engineering reviews.

[155]  R. Schowen,et al.  Secondary structure and protein deamidation. , 1999, Journal of pharmaceutical sciences.

[156]  A. Shafferman,et al.  Modulation of circulatory residence of recombinant acetylcholinesterase through biochemical or genetic manipulation of sialylation levels. , 1998, The Biochemical journal.

[157]  M. Höglund.  Glycosylated and non-glycosylated recombinant human granulocyte colony-stimulating factor (rhG-CSF)—what is the difference? , 1998, Medical oncology.

[158]  A. Whitty,et al.  The structure of human interferon-β: implications for activity , 1998, Cellular and Molecular Life Sciences CMLS.

[159]  R. Venkatesh,et al.  Retardation of thermal and urea induced inactivation of alpha-chymotrypsin by modification with carbohydrate polymers. , 1998, Protein engineering.

[160]  R. Desnick,et al.  Human alpha-galactosidase A: glycosylation site 3 is essential for enzyme solubility. , 1998, The Biochemical journal.

[161]  W. Kisiel,et al.  Functional consequences of mutations in Ser-52 and Ser-60 in human blood coagulation factor VII. , 1998, Archives of biochemistry and biophysics.

[162]  Chi‐Huey Wong,et al.  Enzyme action in glycoprotein synthesis , 1998, Cellular and Molecular Life Sciences CMLS.

[163]  R. Kaptein,et al.  Mobilities of the Inner Three Core Residues and the Man(α1→6) Branch of the Glycan at Asn78 of the α-Subunit of Human Chorionic Gonadotropin Are Restricted by the Protein† , 1998 .

[164]  A. Munafo,et al.  Clinical pharmacology of recombinant human luteinizing hormone: Part I. Pharmacokinetics after intravenous administration to healthy female volunteers and comparison with urinary human luteinizing hormone. , 1998, Fertility and sterility.

[165]  A. Munafo,et al.  Pharmacokinetic and pharmacodynamic interactions between recombinant human luteinizing hormone and recombinant human follicle-stimulating hormone. , 1998, Fertility and sterility.

[166]  A. Munafo,et al.  Clinical pharmacology of recombinant human luteinizing hormone: Part II. Bioavailability of recombinant human luteinizing hormone assessed with an immunoassay and an in vitro bioassay. , 1998, Fertility and sterility.

[167]  R. Kaptein,et al.  Mobilities of the inner three core residues and the Man(alpha 1--6) branch of the glycan at Asn78 of the alpha-subunit of human chorionic gonadotropin are restricted by the protein. , 1998, Biochemistry.

[168]  A. Whitty,et al.  Structural and functional differences between glycosylated and non-glycosylated forms of human interferon-beta (IFN-beta). , 1998, Pharmaceutical research.

[169]  D. Volkin,et al.  Degradative covalent reactions important to protein stability , 1997, Molecular biotechnology.

[170]  T. Hayakawa,et al.  Effect of active oxygen radicals on protein and carbohydrate moieties of recombinant human erythropoietin. , 1997, Free radical research.

[171]  G. Gregoriadis,et al.  Polysialylated asparaginase: preparation, activity and pharmacokinetics. , 1997, Biochimica et biophysica acta.

[172]  Y. Ashani,et al.  Structure of glycan moieties responsible for the extended circulatory life time of fetal bovine serum acetylcholinesterase and equine serum butyrylcholinesterase. , 1997, Biochemistry.

[173]  M. Yu,et al.  Effect of glycosylation on the stability of alpha1-antitrypsin toward urea denaturation and thermal deactivation. , 1997, Biochimica et biophysica acta.

[174]  T. Weinstein,et al.  Distribution of glycosaminoglycans in rat renal tubular epithelium. , 1997, Journal of the American Society of Nephrology : JASN.

[175]  P. Burgon,et al.  In vivo bioactivities and clearance patterns of highly purified human luteinizing hormone isoforms. , 1996, Endocrinology.

[176]  R. Rocchi,et al.  Opioid receptor affinity and analgesic activity of O- and C-glycosylated opioid peptides. , 1996, Acta physiologica Hungarica.

[177]  J. Kihlberg,et al.  Glycosylated peptide hormones: pharmacological properties and conformational studies of analogues of [1-desamino,8-D-arginine]vasopressin. , 1995, Journal of medicinal chemistry.

[178]  S. W. Kim,et al.  Physical stabilization of insulin by glycosylation. , 1995, Journal of pharmaceutical sciences.

[179]  A. Jones,et al.  Carbohydrate does not modulate the in vivo effects of injected interleukin-3. , 1994, Experimental hematology.

[180]  B. Weintraub,et al.  Structure-function studies of oligosaccharides of recombinant human thyrotrophin by sequential deglycosylation and resialylation. , 1994, Glycobiology.

[181]  P. Laduron,et al.  From receptor internalization to nuclear translocation. New targets for long-term pharmacology. , 1994, Biochemical pharmacology.

[182]  R. Dwek,et al.  Glycoforms modify the dynamic stability and functional activity of an enzyme. , 1994, Biochemistry.

[183]  Meir Shinitzky,et al.  Structural and functional aspects , 1994 .

[184]  M. Ono.  Physicochemical and biochemical characteristics of glycosylated recombinant human granulocyte colony stimulating factor (lenograstim). , 1994, European journal of cancer.

[185]  C. Nissen.  Glycosylation of recombinant human granulocyte colony stimulating factor: implications for stability and potency. , 1994, European journal of cancer.

[186]  N. Sharon,et al.  Protein glycosylation. Structural and functional aspects. , 1993, European journal of biochemistry.

[187]  J. Montastruc,et al.  [Mechanism of receptor regulation during repeated administration of drugs]. , 1993, Therapie.

[188]  K. Cantell,et al.  Effect of carbohydrates on the pharmacokinetics of human interferon-gamma. , 1993, Journal of interferon research.

[189]  M. Nomura,et al.  N-linked sugar chain structure of recombinant human lymphotoxin produced by CHO cells: the functional role of carbohydrate as to its lectin-like character and clearance velocity. , 1993, Archives of biochemistry and biophysics.

[190]  G. C. Davis.  Protein stability: impact upon protein pharmaceuticals. , 1993, Biologicals : journal of the International Association of Biological Standardization.

[191]  A. Varki,et al.  Biological roles of oligosaccharides: all of the theories are correct , 1993, Glycobiology.

[192]  N. Nissen,et al.  Comparative pharmacokinetics of single‐dose administration of mammalian and bacterially‐derived recombinant human granulocyte‐macrophage colony‐stimulating factor , 1993, European journal of haematology.

[193]  G. Fricker,et al.  SDZ CO 611: a highly potent glycated analog of somatostatin with improved oral activity. , 1993, Life sciences.

[194]  J. Kuiper,et al.  Mechanisms of Tissue‐type Plasminogn Activator (tPA) Clearance by the Liver a , 1992, Annals of the New York Academy of Sciences.

[195]  G. Winter,et al.  Blood clearance in the rat of a recombinant mouse monoclonal antibody lacking the N-linked oligosaccharide side chains of the CH2 domains. , 1992, Molecular immunology.

[196]  S. Kumar,et al.  Circulatory half-life but not interaction with the lutropin/chorionic gonadotropin receptor is modulated by sulfation of bovine lutropin oligosaccharides. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[197]  D. Liu,et al.  Glycoprotein pharmaceuticals: scientific and regulatory considerations, and the US Orphan Drug Act. , 1992, Trends in biotechnology.

[198]  T. Arakawa,et al.  The effect of carbohydrate on the structure and stability of erythropoietin. , 1991, The Journal of biological chemistry.

[199]  C. Halstenson,et al.  Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta , 1991, Clinical pharmacology and therapeutics.

[200]  M. Takeuchi,et al.  Structures and functional roles of the sugar chains of human erythropoietins. , 1991, Glycobiology.

[201]  L. Sennello,et al.  igh sialic acid content slows prourokinase turnover in rabbits. , 1991, Thrombosis research.

[202]  M. Krieger,et al.  The importance of N- and O-linked oligosaccharides for the biosynthesis and in vitro and in vivo biologic activities of erythropoietin. , 1991, Blood.

[203]  J. Walls,et al.  Glycosylation of human protein C affects its secretion, processing, functional activities, and activation by thrombin. , 1991, The Journal of biological chemistry.

[204]  A. Morell,et al.  Structural characteristics and regulation of the asialoglycoprotein receptor. , 1991, Targeted diagnosis and therapy.

[205]  M. Sporn,et al.  Recombinant latent transforming growth factor beta 1 has a longer plasma half-life in rats than active transforming growth factor beta 1, and a different tissue distribution. , 1990, The Journal of clinical investigation.

[206]  T. Kakutani,et al.  The pharmacokinetic pattern of glycosylated human recombinant lymphotoxin (LT) in rats after intravenous administration. , 1990, Journal of pharmacobio-dynamics.

[207]  K. Hattori,et al.  O-linked sugar chain of human granulocyte colony-stimulating factor protects it against polymerization and denaturation allowing it to retain its biological activity. , 1990, The Journal of biological chemistry.

[208]  B. Fauser,et al.  In vitro and in vivo bioactivity of recombinant human follicle-stimulating hormone and partially deglycosylated variants secreted by transfected eukaryotic cell lines. , 1990, Endocrinology.

[209]  S. Kornfeld,et al.  Lysosomal enzyme targeting. , 1990, Biochemical Society transactions.

[210]  S. Masuda,et al.  The role of carbohydrate in recombinant human erythropoietin. , 1990, European journal of biochemistry.

[211]  Pace Cn,et al.  Measuring and increasing protein stability , 1990 .

[212]  C. Pace,et al.  Conformational stability of globular proteins. , 1990, Trends in biochemical sciences.

[213]  P. Heinrich,et al.  Involvement of various organs in the initial plasma clearance of differently glycosylated rat liver secretory proteins. , 1988, European journal of biochemistry.

[214]  B. Sobel,et al.  Biochemical determinants of clearance of tissue-type plasminogen activator from the circulation. , 1988, Circulation.

[215]  P. Heinrich,et al.  The role of N-glycosylation for the plasma clearance of rat liver secretory glycoproteins. , 1989, European journal of biochemistry.

[216]  J. Soria,et al.  Glycosylation of human fibrinogen and fibrin in vitro. Its consequences on the properties of fibrin(ogen). , 1987, Thrombosis research.

[217]  J. Peter-Katalinic,et al.  Structure of the carbohydrate moiety of human interferon-beta secreted by a recombinant Chinese hamster ovary cell line. , 1987, The Journal of biological chemistry.

[218]  G. Murray.  Lectin-specific targeting of lysosomal enzymes to reticuloendothelial cells. , 1987, Methods in enzymology.

[219]  A. Schwartz,et al.  Receptor-mediated endocytosis. , 1986, The Journal of clinical investigation.

[220]  B. Weintraub,et al.  Glycosylation of thyroid-stimulating hormone in pituitary tumor cells: influence of high mannose oligosaccharide units on subunit aggregation, combination, and intracellular degradation. , 1983, Endocrinology.

[221]  G. Pessina,et al.  Renal metabolism of homologous serum interferon. , 1983, Antiviral research.

[222]  P. Stahl,et al.  Isolation and characterization of a mannose/N-acetylglucosamine/fucose-binding protein from rat liver. , 1981, The Biochemical journal.

[223]  C. Steer,et al.  Uptake and distribution of placental glucocerebrosidase in rat hepatic cells and effects of sequential deglycosylation. , 1981, Biochimica et biophysica acta.

[224]  J. Minta.  The role of sialic acid in the functional activity and the hepatic clearance of C1-INH. , 1981, Journal of immunology.

[225]  P. Schlesinger,et al.  The role of extra-hepatic tissues in the receptor-mediated plasma clearance of glycoproteins terminated by mannose or N-acetylglucosamine. , 1980, The Biochemical journal.

[226]  P. Schlesinger,et al.  Plasma clearance of glycoproteins with terminal mannose and N-acetylglucosamine by liver non-parenchymal cells. Studies with beta-glucuronidase, N-acetyl-beta-D-glucosaminidase, ribonuclease B and agalacto-orosomucoid. , 1978, The Biochemical journal.

[227]  W. Sly,et al.  Human β-glucuronidase: In vivo clearance and in vitro uptake by a glycoprotein recognition system on reticuloendothelial cells , 1978, Cell.

[228]  R. Brady,et al.  The uptake of agalacto‐glucocerebrosidase by rat hepatocytes and kupffer cells , 1978, FEBS letters.

[229]  R. Brady,et al.  The uptake of native and desialylated glucocerebrosidase by rat hepatocytes and Kupffer cells. , 1978, Biochemical and biophysical research communications.

[230]  Mark J. Miller,et al.  Evidence for receptor-mediated binding of glycoproteins, glycoconjugates, and lysosomal glycosidases by alveolar macrophages. , 1978, Proceedings of the National Academy of Sciences of the United States of America.

[231]  J. Baynes,et al.  Effect of glycosylation on the in vivo circulating half-life of ribonuclease. , 1976, The Journal of biological chemistry.

[232]  G. Vegarud,et al.  Glycosylation of Proteins: a new method of enzyme stabilization. , 1975, Biotechnology and bioengineering.

[233]  G. Vegarud,et al.  The resistance of glycoproteins to proteolytic inactivation. , 1975, Acta chemica Scandinavica. Series B: Organic chemistry and biochemistry.

[234]  A. Morell,et al.  The role of surface carbohydrates in the hepatic recognition and transport of circulating glycoproteins. , 2006, Advances in enzymology and related areas of molecular biology.

[235]  A. Morell,et al.  [87] A membrane receptor protein for asialoglycoproteins , 1974 .

[236]  A. Morell,et al.  A membrane receptor protein for asialoglycoproteins. , 1974, Methods in enzymology.

[237]  T. Waldmann,et al.  The role of the kidney in the metabolism of plasma proteins. , 1974, Nephron.

[238]  A. Morell,et al.  The dual role of sialic acid in the hepatic recognition and catabolism of serum glycoproteins. , 1974, Biochemical Society symposium.

[239]  G. Gregoriadis,et al.  The role of sialic acid in determining the survival of glycoproteins in the circulation. , 1971, The Journal of biological chemistry.

[240]  I. Sternlieb,et al.  Physical and chemical studies on ceruloplasmin. V. Metabolic studies on sialic acid-free ceruloplasmin in vivo. , 1968, The Journal of biological chemistry.